We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00137787
Recruitment Status : Unknown
Verified November 2008 by Center for Supporting Hematology-Oncology Trials.
Recruitment status was:  Recruiting
First Posted : August 30, 2005
Last Update Posted : November 13, 2008
Sponsor:
Collaborator:
Bayer
Information provided by:
Center for Supporting Hematology-Oncology Trials

Brief Summary:
The aim of this study is to investigate whether intravenous ciprofloxacin is as effective as cefepime for the initial treatment of febrile neutropenia developed in patients with hematologic diseases.

Condition or disease Intervention/treatment Phase
Febrile Neutropenia Drug: ciprofloxacin Drug: cefepime Phase 3

Detailed Description:
Infectious complications during neutropenic periods are major causes of morbidity and mortality especially for patients with hematological diseases, and prompt initiation of antibiotic therapy is warranted for those who develop febrile neutropenia. As for initial therapeutic agents, beta-lactam antibiotics, i.e., third- or fourth-generation cephalosporins and carbapenems have been used frequently because of their strong and broad-spectrum of action. However, under these conditions, development of resistance mediated by a beta-lactamase is concerned, and there is a need for alternative non-beta-lactam antibiotics for this indication. Ciprofloxacin is a potent agent covering against wide range of strains including Pseudomonas aeruginosa, and expected as a potential candidate. We have therefore planned a prospective randomized controlled trial designed to compare intravenous ciprofloxacin with cefepime for febrile neutropenic patients.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Controlled Trial Comparing Ciprofloxacin With Cefepime in Febrile Neutropenic Patients With Hematologic Diseases
Study Start Date : April 2005
Estimated Primary Completion Date : December 2009
Estimated Study Completion Date : March 2010


Arm Intervention/treatment
Experimental: 1 Drug: ciprofloxacin
Active Comparator: 2 Drug: cefepime



Primary Outcome Measures :
  1. Treatment efficacy [ Time Frame: At 7 days after initiating therapy ]

Secondary Outcome Measures :
  1. Treatment efficacy [ Time Frame: At 21 days ]
  2. Toxicity [ Time Frame: During the follow-up period ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   15 Years to 79 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Hematologic disease
  • Ages between 15 and 79 years
  • Axillary temperature of 38.0 C or greater on one occasion or of 37.5 to 37.9 C lasting for more than 1 hour
  • Absolute neutrophil count of less than 500/microL
  • T-Bil level less than 2.0 times the upper limit of normal
  • Cre level less than 1.5 times the upper limit of normal
  • Written informed consent

Exclusion Criteria:

  • Past history of allergic reaction to the study drug
  • Positive for HIV antibody
  • Pregnant or lactating women
  • Family history of auditory disturbance
  • Having received systemic antibacterial therapy within 14 days
  • Receiving systemic antifungal or antiviral therapy except fluconazole or acyclovir for cases undergoing transplantation
  • No recovery of neutrophil count of 1,000/microL or higher from the previous febrile episode
  • On treatment with ketoprofen
  • On treatment with sodium valproate
  • Septic shock

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00137787


Contacts
Contact: Yoshiko Atsuta, MD 81-52-719-1973 y-atsuta@med.nagoya-u.ac.jp
Contact: Ritsuro Suzuki, MD r-suzuki@med.nagoya-u.ac.jp

Locations
Japan
Nagoya University Graduate School of Medicine Recruiting
Nagoya, Japan, 466-8550
Contact: Yoshiko Atsuta, MD    81-52-719-1973    y-atsuta@med.nagoya-u.ac.jp   
Principal Investigator: Tomoki Naoe, MD         
Sponsors and Collaborators
Center for Supporting Hematology-Oncology Trials
Bayer
Investigators
Study Director: Yoshiko Atsuta, MD Nagoya University

Additional Information:
ClinicalTrials.gov Identifier: NCT00137787     History of Changes
Other Study ID Numbers: C-SHOT 0402
First Posted: August 30, 2005    Key Record Dates
Last Update Posted: November 13, 2008
Last Verified: November 2008

Keywords provided by Center for Supporting Hematology-Oncology Trials:
febrile neutropenia
hematologic disease

Additional relevant MeSH terms:
Neutropenia
Fever
Hematologic Diseases
Febrile Neutropenia
Agranulocytosis
Leukopenia
Leukocyte Disorders
Body Temperature Changes
Signs and Symptoms
Ciprofloxacin
Cefepime
Cephalosporins
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 Enzyme Inhibitors